• Je něco špatně v tomto záznamu ?

Age-associated prognostic and predictive biomarkers in patients with breast cancer

M. Kolečková, Z. Kolář, J. Ehrmann, G. Kořínková, R. Trojanec

. 2017 ; 13 (6) : 4201-4207. [pub] 20170406

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22008139

Grantová podpora
NV16-31997A MZ0 CEP - Centrální evidence projektů

To date, no comprehensive prognostic or predictive marker profiling analysis has been performed in association with the age of patients with breast cancer. In the present study, 632 breast cancer tissue samples were analyzed for expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), B-cell lymphoma (Bcl)-2 protein, HER2 gene amplification, proliferation [as evaluated by proliferating cell nuclear antigen (PCNA) and Ki-67 index], tumor grade, histological type and molecular subtype. The data revealed correlations with the age of patients. A statistically significant positive correlation was identified between patient age and expression of ER (P<0.0001). There was no significant association between patient age and PR, HER2 protein expression, HER2 gene amplification or PCNA. A significant negative correlation between age and Ki-67 expression (P<0.0001) as well as grade of tumor (P=0.007) was identified. The spectrum of molecular subtypes differed according to age (P=0.0003). The highest incidence of aggressive triple-negative and HER2-positive breast cancer was present in patients aged between 20 and 39 years. Luminal A subtype was the most frequent cancer subtype in patients from age 40 onwards, where proliferation activity declined with age and expression of hormone receptors increased along with Bcl-2 expression. Aggressive forms of breast cancer were more common in younger patients. Prognostic and predictive markers have a complex age-specific distribution. The findings of less aggressive luminal A and B subtypes in older patients, and the positive correlation with ER, PR and Bcl-2 expression reveal the potential efficacy of Bcl-2 as a marker of hormone responsiveness in these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22008139
003      
CZ-PrNML
005      
20230110084537.0
007      
ta
008      
220315s2017 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/ol.2017.6000 $2 doi
035    __
$a (PubMed)28599421
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Kolečková, Markéta, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $d 1990- $7 xx0238146
245    10
$a Age-associated prognostic and predictive biomarkers in patients with breast cancer / $c M. Kolečková, Z. Kolář, J. Ehrmann, G. Kořínková, R. Trojanec
520    9_
$a To date, no comprehensive prognostic or predictive marker profiling analysis has been performed in association with the age of patients with breast cancer. In the present study, 632 breast cancer tissue samples were analyzed for expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), B-cell lymphoma (Bcl)-2 protein, HER2 gene amplification, proliferation [as evaluated by proliferating cell nuclear antigen (PCNA) and Ki-67 index], tumor grade, histological type and molecular subtype. The data revealed correlations with the age of patients. A statistically significant positive correlation was identified between patient age and expression of ER (P<0.0001). There was no significant association between patient age and PR, HER2 protein expression, HER2 gene amplification or PCNA. A significant negative correlation between age and Ki-67 expression (P<0.0001) as well as grade of tumor (P=0.007) was identified. The spectrum of molecular subtypes differed according to age (P=0.0003). The highest incidence of aggressive triple-negative and HER2-positive breast cancer was present in patients aged between 20 and 39 years. Luminal A subtype was the most frequent cancer subtype in patients from age 40 onwards, where proliferation activity declined with age and expression of hormone receptors increased along with Bcl-2 expression. Aggressive forms of breast cancer were more common in younger patients. Prognostic and predictive markers have a complex age-specific distribution. The findings of less aggressive luminal A and B subtypes in older patients, and the positive correlation with ER, PR and Bcl-2 expression reveal the potential efficacy of Bcl-2 as a marker of hormone responsiveness in these patients.
650    17
$a nádory prsu $x epidemiologie $7 D001943 $2 czmesh
650    17
$a věkové faktory $7 D000367 $2 czmesh
650    _7
$a nádorové biomarkery $x chemie $7 D014408 $2 czmesh
650    _7
$a prognóza $7 D011379 $2 czmesh
650    _7
$a imunohistochemie $x metody $7 D007150 $2 czmesh
650    _7
$a diagnostické techniky molekulární $x metody $7 D025202 $2 czmesh
650    _7
$a lidé $7 D006801 $2 czmesh
650    _7
$a ženské pohlaví $7 D005260 $2 czmesh
655    _2
$a časopisecké články $7 D016428
655    _7
$a práce podpořená grantem $7 D013485 $2 czmesh
700    1_
$a Kolář, Zdeněk, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $d 1953- $7 jn20000710256
700    1_
$a Ehrmann, Jiří, $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $d 1967- $7 jo2003163162
700    1_
$a Kořínková, Gabriela $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $7 xx0087788
700    1_
$a Trojanec, Radek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-775 15 Olomouc, Czech Republic $7 xx0074936
773    0_
$w MED00193499 $t Oncology letters $x 1792-1074 $g Roč. 13, č. 6 (2017), s. 4201-4207
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28599421 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220315 $b ABA008
991    __
$a 20230110084534 $b ABA008
999    __
$a kom $b bmc $g 1770179 $s 1159333
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 13 $c 6 $d 4201-4207 $e 20170406 $i 1792-1074 $m Oncology letters $n Oncol Lett $x MED00193499
GRA    __
$a NV16-31997A $p MZ0
LZP    __
$c NLK120 $d 20230110 $a 2021-granty

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...